DEBORAH FALLON: Open Payments
NPI 1639243561 · CAMERON PARK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,797 in 196 payments from 15 companies in 2025. Trend: 2023 $5,692 · 2024 $5,450 · 2025 $4,797
Food & beverage: $4,797
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $721 |
| Otsuka America Pharmaceutical, Inc. | 25 | $702 |
| Teva Pharmaceuticals USA, Inc. | 27 | $694 |
| Neurocrine BioSciences, Inc. | 18 | $643 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 35 | $558 |
| Vanda Pharmaceuticals Inc. | 15 | $332 |
| Janssen Pharmaceuticals, Inc | 7 | $247 |
| Alkermes, Inc. | 10 | $243 |
| Lundbeck LLC | 11 | $217 |
| E.R. Squibb & Sons, L.L.C. | 4 | $192 |
Products named: VRAYLAR, REXULTI, INGREZZA, CAPLYTA, UZEDY, AUSTEDO XR, ARISTADA, HETLIOZ.
Industry payments across CA — which companies pay providers there.
